These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31071349)

  • 1. Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance.
    Dai C; Ganesan V; Nyame YA; Almassi N; Greene DJ; Hettel D; Magi-Galluzzi C; Gong M; Jones JS; Stephenson AJ; Berglund RK; Klein EA
    Urology; 2019 Aug; 130():106-112. PubMed ID: 31071349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance?
    Satasivam P; Poon BY; Ehdaie B; Vickers AJ; Eastham JA
    J Urol; 2016 Jan; 195(1):74-9. PubMed ID: 26192258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
    J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
    Waisman Malaret AJ; Chang P; Zhu K; Zheng Y; Newcomb LF; Liu M; McKenney JK; Brooks JD; Carroll P; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Lin DW; Wagner AA
    J Urol; 2022 Apr; 207(4):805-813. PubMed ID: 34854745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
    Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
    Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.
    Komisarenko M; Wong LM; Richard PO; Timilshina N; Toi A; Evans A; Zlotta A; Kulkarni G; Hamilton R; Fleshner N; Finelli A
    J Urol; 2016 Feb; 195(2):307-12. PubMed ID: 26417646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
    Bratt O; Holmberg E; Andrén O; Carlsson S; Drevin L; Johansson E; Josefsson A; Nyberg M; Sandberg J; Stattin P; Robinsson D
    Eur Urol; 2019 Oct; 76(4):461-466. PubMed ID: 30878303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance.
    Ganesan V; Dai C; Nyame YA; Greene DJ; Almassi N; Hettel D; Zabell J; Arora H; Haywood S; Crane A; Reichard C; Zampini A; Elshafei A; Stein RJ; Fareed K; Jones JS; Gong M; Stephenson AJ; Klein EA; Berglund RK
    Urology; 2017 Sep; 107():184-189. PubMed ID: 28625591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
    BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
    Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
    Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer.
    O'Connor LP; Wang AZ; Yerram NK; Lebastchi AH; Ahdoot M; Gurram S; Zeng J; Mehralivand S; Harmon S; Merino MJ; Parnes HL; Choyke PL; Turkbey B; Wood BJ; Pinto PA
    Urology; 2020 Oct; 144():164-170. PubMed ID: 32679272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance.
    Anderson CB; Sternberg IA; Karen-Paz G; Kim PH; Sjoberg D; Vargas HA; Touijer K; Eastham JA; Ehdaie B
    J Urol; 2015 Dec; 194(6):1607-11. PubMed ID: 26119671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
    Perera M; Jibara G; Tin AL; Haywood S; Sjoberg DD; Benfante NE; Carlsson SV; Eastham JA; Laudone V; Touijer KA; Fine S; Scardino PT; Vickers AJ; Ehdaie B
    Eur Urol Focus; 2023 Jul; 9(4):662-668. PubMed ID: 36566100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Pennisi M; Morgia G
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
    Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
    J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.